The U.S. Food and Drug Administration (FDA) has cleared the start of clinical testing of FT839, Fate Therapeutics’ experimental off-the-shelf CAR T-cell therapy for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans to launch a basket Phase 1/2 clinical trial to evaluate FT839 in combination with…
Discussion
On a Wednesday, I received a call that my surgeon wanted to move up my cervical spinal fusion because the damage from my bones pressing into my spinal cord was too serious to wait. It would take place less than 48 hours later, on that Friday. But when Friday morning…
Discussion
Blood cell ratios derived from routine blood tests may help distinguish people with active ANCA-associated vasculitis (AAV) from those in glucocorticoid-free remission, independent of age and sex, according to a new study. “Our findings suggested that these readily available, standardized, low-cost biomarkers make them attractive candidates for integration into…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
